SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Chamberlain MC,Kormanik PA. Practical guidelines for the treatment of malignant gliomas. West J Med. 1998; 168: 114120.
  • 2
    Fine HA,Dear KB,Loeffler JS, et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer. 1993; 71: 25852597.
  • 3
    Cairncross G,Macdonald D,Ludwin S, et al. Chemotherapy for anaplastic oligodendroglioma.National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1994; 12: 20132021.
  • 4
    Glass J,Hochberg FH,Gruber ML, et al. The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J Neurosurg. 1992; 76: 741745.
  • 5
    Newlands ES,Blackledge GR,Slack JA, et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer. 1992; 65: 287291.
  • 6
    Stupp R,Ostermann S,Leyvraz S, et al. Cerebrospinal fluid levels of temozolomide as a surrogate marker for brain penetration [abstract]. Proc Am Soc Clin Oncol. 2001; 20: 59a.
  • 7
    Plowman J,Waud WR,Koutsoukos AD, et al. Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res. 1994; 54: 37933799.
  • 8
    Friedman HS,Dolan ME,Pegg AE, et al. Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res. 1995; 55: 28532857.
  • 9
    Newlands ES,O'Reilly SM,Glaser MG, et al. The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer. 1996; 32A: 22362241.
  • 10
    Harris MT,Rosenthal MA,Ashley DL, et al. An Australian experience with temozolomide for the treatment of recurrent high grade gliomas. J Clin Neurosci. 2001; 8: 325327.
  • 11
    Yung WKA,Albright RE,Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000; 83: 588593.
  • 12
    Wedge SR,Porteus JK,May BL, et al. Potentiation of temozolomide and BCNU cytotoxicity by O-benzylguanine: a comparative study in vitro. Br J Cancer. 1996; 73: 482490.
  • 13
    Stevens MF,Hickman JA,Langdon SP, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-1 (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res. 1987; 47: 58465852.
  • 14
    Brock CS,Newlands ES,Wedge SR, et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res. 1998; 58: 43634367.
  • 15
    Newlands ES,Stevens MF,Wedge SR, et al. Temozolomide: a review of its discovery, chemical properties, preclinical development and clinical trials. Cancer Treat Rev. 1997; 23: 3561.
  • 16
    Middleton MR,Lee SM,Arance A, et al. O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study. Int J Cancer. 2000; 88: 469473.
  • 17
    Gerson SL,Spiro TP,Reidenberg P, et al. Rapid depletion of O6-alkylguanine DNA alkyltransferase with twice daily oral temozolomide (SCH 52365) in patients with advanced cancer [abstract]. Proc Am Soc Clin Oncol. 1996; 15: 178.
  • 18
    Yung WK,Prados MD,Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol. 1999; 17: 27622771.
  • 19
    Chinot O-L,Honore S,Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol. 2001; 19: 24492455.
  • 20
    Brada M,Hoang-Xuan K,Rampling R, et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol. 2001; 12: 259266.
  • 21
    Khan RB,Raizer JJ,Malkin MG, et al. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro Oncol. 2002; 4: 3943.
  • 22
    Macdonald DR,Cascino TL,Schold SC, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990; 8: 12771280.
  • 23
    Collett D. Modeling Survival Data in Medical Research. London: Chapman & Hall; 1993: 7886.
  • 24
    Tolcher AW,Gerson SL,Denis L, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer. 2003; 88: 10041011.
  • 25
    de Bono J,Denis L,Patnaik A, et al. Extended temozolomide (TMZ) dosing schedules permit the administration of higher TMZ dose intensities and inhibit the DNA repair enzyme O6-alkylguanine DNA alkyltransferase (AGAT) [abstract]. Eur J Cancer. 2001; 37( suppl 6): S31S32.
  • 26
    Spiro TP,Liu L,Majka S, et al. Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O6-alkylguanine-DNA-alkyltransferase. Clin Cancer Res. 2001; 7: 23092317.
  • 27
    Wick W,Steinbach JP,Kuker WM, et al. One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology. 2004; 62: 21132115.
  • 28
    van den Bent MJ,Keime-Guibert F,Brandes AA, et al. Temozolomide chemotherapy in recurrent oligodendroglioma. Neurology. 2001; 57: 340342.